Question to pose

[Dogonenuts]

With the OS in the Imbark trial now up to 19-21 months, would a new treatment paradigm be worth considering? Would not combination therapy from the outset seem more reasonable, though expensive? Or, even imet from the start and splenectomy if a bonemarrow biopsy and aspirate show reversal of marrow fibrosis and thus return of normal hematpoesis. This would be cheaper than continuing Jakafi purely for symptomatic relief knowing that when the patients fail Jakfi they will be in worse shape.

[biopearl]

Dogonenuts, you are WAY ahead of yourself. There will be not combination therapy until there are studies to support this approach. There might not even be front line single therapy in MF without further study (some info available from Mayo) but unless physicians use the drug off label which they might, further study for both single drug and combination therapy will probably be required. bp

[Dogonenuts]

Oh, I know there would have to be some studies. Just thinking where this thing might go over the next few years and why JnJ might jump whole hog for GERN.

[biopearl]

You are right about that. The Janssen "skunk works" lab studies have probably opened many doors which remain unknown to us. Judging by the last patent filing many many doors. bp